Group 1: 康方生物 - Company maintains a "Buy" rating for 康方生物 with a target price of HKD 185.80, expecting product sales revenue to reach HKD 3 billion in 2025, a 52% year-on-year increase, driven by Cadonilimab and Ivonescimab entering the national medical insurance directory [1] - Ivonescimab has shown significant improvement in progression-free survival in head-to-head Phase III clinical trials, with key global data readout imminent [1] - The FDA review target date for EGFR-TKI resistant NSCLC indication is set for November 2026, potentially marking the company's first FDA-approved product [1] Group 2: 中国铁塔 - Company maintains a "Hold" rating for 中国铁塔 with a target price of HKD 12.10, projecting a 2.7% revenue growth to HKD 100.4 billion in 2025, and an 8.4% net profit increase to HKD 11.6 billion [1] - Revenue from the communication tower business is expected to decline by 0.3% year-on-year due to continued capital expenditure reductions from the three major operators [1] - DAS and "two wings" businesses are anticipated to maintain double-digit growth, contributing to revenue diversification [1] Group 3: 信达生物 - Company maintains a "Buy" rating for 信达生物 with a target price of HKD 113.86, forecasting a first-time annual profit of HKD 834 million in 2025, with product sales revenue reaching HKD 11.9 billion, a 45% year-on-year increase [2] - Key growth drivers include newly launched products Mazdutide, PCSK9 monoclonal antibody, and IGF-1R antibody [2] - Collaboration with Takeda to advance IBI363 into global Phase III clinical trials, with multiple assets entering or nearing global multi-center Phase III [2] Group 4: TCL电子 - Company maintains a "Buy" rating for TCL电子, expecting 2025 revenue of HKD 114.6 billion, a 15.4% year-on-year increase, and a net profit of HKD 2.5 billion, a 41.8% increase [3] - Growth is primarily driven by a 15.7% increase in overseas television revenue, a doubling of Mini LED shipments, and a 63.6% surge in photovoltaic business revenue [3] - Joint venture with Sony is imminent, expected to enhance high-end channel access and improve profitability [3] Group 5: 小马智行-W - Company maintains a "Buy" rating for 小马智行-W with a target price of HKD 195, projecting a 129% year-on-year increase in Robotaxi revenue in 2025 [4] - Achieved positive unit economics in Guangzhou and Shenzhen, with peak daily revenue per vehicle reaching HKD 394 [4] - The BOM cost of the seventh-generation model has decreased by 20% compared to the previous generation, with plans to expand the fleet to 3,000 vehicles [4] Group 6: 优然牧业 - Company maintains a "Buy" rating for 优然牧业, forecasting a 13.2% increase in raw milk sales volume to 4.15 million tons in 2025, with per cow production rising to 12.8 tons/year [5] - Feed cost per kilogram of milk is expected to decrease by 10.5%, with cash EBITDA reaching HKD 5.59 billion, a 4.9% year-on-year growth [5] - Anticipation of a dual-cycle resonance point for milk and meat prices in 2026 due to ongoing industry capacity reduction and rising beef prices [5] Group 7: 移卡 - Company maintains an "Outperform" rating for 移卡 with a target price of HKD 8.90, projecting a domestic payment rate increase to 12.3 bps and a 3.2-fold increase in overseas GPV to HKD 4.7 billion in 2025 [6] - This growth is expected to drive an 8% increase in acquiring revenue [6] - Integration of AI throughout the operational process has led to a 13% reduction in sales and management expenses, with core EBITDA growing by 53% to HKD 350 million [6] Group 8: 中国民航信息网络 - Company maintains a "Buy" rating for 中国民航信息网络 with a target price of HKD 15.70, expecting a 4.9% growth in aviation information technology processing volume and an 18.8% increase in revenue from smart travel products and services in 2025 [7] - Revenue from airport digital services is projected to decline by 20.8% due to construction schedule impacts, but significant cost reductions in depreciation and amortization are expected to enhance operating profit margins by 3.6 percentage points to 30.9% [7] Group 9: 碧桂园服务 - Company maintains an "Accumulate" rating for 碧桂园服务 with a target price of HKD 7.24, forecasting a 10% revenue growth to HKD 48.35 billion in 2025, while core net profit is expected to decline by 17% to HKD 2.52 billion [8] - The decline is attributed to pressure on community value-added services and increased impairment of receivables [8] - Annualized revenue growth from market expansion is projected to reach 87% to HKD 2.03 billion, with a significant increase in shareholder returns, raising the dividend payout ratio to 60% [8] Group 10: 赤子城科技 - Company maintains an "Accumulate" rating for 赤子城科技, projecting a 32.9% year-on-year increase in social business revenue to HKD 6.14 billion in 2025 [9] - Revenue from SUGO and TopTop is expected to grow by over 80% and 70%, respectively, with rapid expansion in emerging markets such as Latin America and Japan [9] - Innovative business revenue is projected to grow by 59.3%, driven by the launch of AI self-developed models Boomiix and creative community Aippy, forming a second growth curve through "diversified matrix + global expansion" [9]

Core Insights - Akeso reported a record commercial sales revenue of RMB3,033.1 million for 2025, marking a 51.48% year-on-year increase, driven by strong clinical validation and adoption of its products [1][2][14] - The company is advancing its innovative oncology portfolio with the introduction of bispecific and trispecific antibodies, aiming to address unmet medical needs in various cancer types [7][8][10] Commercial Operations - Akeso's products are now fully included in China's National Reimbursement Drug List (NRDL), enhancing market access and positioning for growth in 2026 [1][2] - The company achieved significant sales growth due to the successful adoption of its approved products by healthcare professionals and patients [1][14] Advanced Clinical Development - Ivonescimab, the world's first PD-1/VEGF bispecific antibody, has treated approximately 70,000 patients and has secured two approved lung cancer indications in China [2][4] - Cadonilimab, the first PD-1/CTLA-4 bispecific antibody, has shown clinical benefits across multiple tumor types, with around 120,000 patients treated [5][6] Oncology Therapy Matrix - Akeso is expanding its oncology portfolio through the development of next-generation antibody-drug conjugates (ADCs) and trispecific antibodies, aiming to overcome limitations of traditional ADCs [7][8] - The company is conducting 12 registrational or Phase III clinical trials for cadonilimab, targeting major cancer types and addressing significant unmet medical needs [6][7] AI-Powered R&D - Akeso is integrating AI across its R&D and manufacturing processes, enhancing its drug discovery capabilities and accelerating the development of innovative therapies [11][12] - The company has established a comprehensive AI technology matrix that supports high-precision engineering from sequence design to clinical development [12] Strategic Vision - The company aims to deliver transformative medicines globally, with over ten products in international trials, including ivonescimab and cadonilimab [16] - Akeso is focused on expanding its therapeutic reach beyond oncology into immune-related diseases, leveraging its bispecific and multispecific antibody platforms [10][15]

Core Insights - Akeso, Inc. announced long-term survival analysis data for cadonilimab, a treatment for recurrent or metastatic cervical cancer, showing a 100% 24-month overall survival (OS) rate in complete responders [1] - The study highlights cadonilimab's ability to convert deep tumor remission into long-term disease control and survival benefits, providing a new therapeutic option for advanced cervical cancer patients [1] Survival Outcomes - In a study with a median follow-up of 26.5 months, complete responders had a median OS that was not reached, with a 24-month OS rate of 100.0% [1] - For partial responders, the median OS was also not reached, with a 24-month OS rate of 63% and a median progression-free survival (PFS) of 11.17 months [1] - The 12-month PFS rate for complete responders was 84.6%, while for partial responders it was 47.3% [1] PD-L1 Expression Status - The study included over 18% of patients with PD-L1 CPS < 1, demonstrating that cadonilimab achieved a median OS of 17.5 months across the overall population [1] - Updated data showed durable survival benefits with 18-month and 24-month OS rates of 47.8% and 40.9%, respectively, for both PD-L1 positive and negative patients [1] Cadonilimab's Mechanism and Approval - Cadonilimab is the first approved bispecific antibody cancer immunotherapy, launched in 2022, showing superior efficacy in challenging settings like immunotherapy-resistant tumors [1] - The drug targets both PD-1 and CTLA-4, overcoming limitations of existing therapies and is currently approved for three indications in China [1] Clinical Development and Pipeline - Akeso is advancing cadonilimab's global clinical development and is involved in 11 registrational/Phase III studies across various tumor indications [1] - The company has a robust pipeline of over 50 innovative assets, with 26 candidates in clinical trials and 7 new drugs commercially available [1]

Core Insights - Akeso, Inc. has successfully included all five of its self-developed innovative drugs in the updated National Reimbursement Drug List (NRDL) for 2025, effective January 1, 2026, which enhances patient access to these treatments [1][2][3] Group 1: Drug Inclusion Details - All approved indications for Akeso's five independently commercialized drugs are now part of the NRDL, addressing major tumor diseases and autoimmune disorders prevalent in China [1][2] - Ivonescimab, a first-in-class PD-1/VEGF bispecific antibody, has secured inclusion for its new first-line indication for PD-L1-positive non-small cell lung cancer (NSCLC), demonstrating a 49% reduction in disease progression or death compared to pembrolizumab in clinical trials [3][4] - Cadonilimab, another first-in-class bispecific antibody, has successfully negotiated inclusion for first-line indications in gastric and cervical cancers, showing significant clinical benefits across all patient populations [4] - Penpulimab has achieved NRDL inclusion for all four of its approved indications, including treatments for nasopharyngeal carcinoma and classical Hodgkin lymphoma [5] - Ebdarokimab, targeting IL-12/IL-23, has been included for the treatment of moderate-to-severe psoriasis, marking Akeso's first drug in the autoimmune disease sector [7] - Ebronucimab has secured inclusion for both of its approved indications related to hypercholesterolemia, enhancing its market presence [8] Group 2: Strategic Implications - The successful inclusion of these drugs in the NRDL is expected to reduce the financial burden on patients and provide superior treatment alternatives, thereby addressing significant public health challenges in China [2] - The recognition of these drugs in clinical practice prior to NRDL inclusion indicates their breakthrough clinical value and enhances trust among healthcare providers and patients [2] - This achievement lays a solid foundation for accelerating broader clinical adoption and supports Akeso's ongoing commercialization efforts, positioning the company for sustained growth and global expansion [2][3] Group 3: Company Overview - Akeso is a leading biopharmaceutical company focused on the research, development, manufacturing, and commercialization of innovative biological medicines, with a robust pipeline of over 50 assets in various therapeutic areas [12] - The company utilizes an integrated R&D innovation system and has developed a comprehensive drug development platform, which includes bispecific antibody technology [12] - Akeso aims to provide affordable therapeutic antibodies globally while creating significant commercial and social value, striving to become a leading player in the biopharmaceutical industry [12]

Summary of China Biotech Outlook Industry Overview - The report focuses on the **China biotech industry**, particularly the performance of H-share listed companies in this sector, which has seen significant growth year-to-date (YTD) [1][2][3]. Key Performance Metrics - The average H-share EV/2030e sales multiple in the China biotech space has more than **doubled from 2.0x to 4.2x** YTD, surpassing the previous peak of **3.7x** in 2021 [3][21]. - The overall market cap of H-share listed China biotech companies has expanded by **154% YTD**, compared to **34%** for the Hang Seng Index (HSI) [9][19]. Market Drivers - The valuation re-rating is attributed to the **globalization of China biotech**, with increasing recognition of domestic drug developers' innovations [3][20]. - Anticipated **Fed rate cuts** are expected to boost investor risk appetite, particularly towards growth sectors like China biotech [4][9]. Stock Performance Insights - Stock performance will depend on fundamentals such as successful commercial execution and rapid innovation development [5][19]. - Companies with near-term catalysts (e.g., Akeso, InnoCare), proof-of-concept data (e.g., Keymed), and those positioned to leverage innovation trends (e.g., Innovent, Duality) are expected to outperform [5][19]. Risks and Challenges - Potential risks include persistent valuation premiums that may deter overseas investors and geopolitical tensions that could disrupt cross-border innovation flows [6][19]. Future Outlook - The report suggests that the sector will continue to be supported by the long-term thesis of **China drug innovation** becoming increasingly globalized [6][19]. - The expectation of higher valuations based on long-term forecasts (i.e., 2035e) could lead to further re-ratings across the sector [4][19]. Company-Specific Insights - **Abbisko Cayman Ltd**: Price target raised from **HK$8.30 to HK$22.00** [7][17]. - **Akeso, Inc.**: Price target increased from **HK$87.00 to HK$215.00** [7][17]. - **Duality Biotherapeutics Inc**: Price target raised from **HK$244.00 to HK$493.00** [7][17]. - **Everest Medicines Ltd**: Price target increased from **HK$40.00 to HK$55.00** [7][17]. - **HUTCHMED (China) Ltd**: Price target decreased from **US$18.00 to US$13.75** [7][17]. Valuation Trends - The report indicates a widening discount between Chinese biotech companies with in-house drug discovery capabilities and those relying on external sources [22][25]. - The current valuation band for the China biotech sector is approximately **3x-5x EV/sales**, aligning more closely with US biopharma companies [21][25]. Conclusion - The China biotech sector is at a pivotal inflection point, driven by domestic innovation and increasing global recognition. The anticipated Fed rate cuts and ongoing globalization trends are expected to further enhance the sector's attractiveness to investors [4][19][25].

Business Highlights - Akeso's commercial sales revenue in 2025H1 reached RMB 1.402 billion, a 49% year-on-year increase[16, 24] - The company has 13 Phase III/registrational trials of ivonescimab covering lung cancer and expanding to cold tumors[13] - The company has 10 phase III clinical studies of cadonilimab across lung cancer, gastric cancer, liver cancer and cervical cancer[13] - Penpulimab receives FDA approval in the United States[14] Pipeline Development - Three blockbuster new drug candidates entered clinical stage[19] - Six Phase III clinical trials reached the primary endpoint[20] - Ivonescimab's first global Phase III trial received positive results[84] - Manfidokimab (IL-4Rα) Reached Endpoints in the Registrational Phase III Trial for Atopic Dermatitis[116] Financial Performance - 1H 2025 Revenue reached RMB 1.412 billion, a 33.7% growth from 1H in 2024[16] - The company has cash and short-term financial assets of approximately RMB 7.14 billion[16] - Sales and Marketing expense as a percentage of sales decreased from 55% in 2024H1 to 48% in 2025 H1[136, 140]